EGFR and adenocarcinoma: It is unclear whether the potential benefit of TKIs for patients with wild type EGFR would persist if compared for example, with pemetrexed (for patients with adenocarcinoma) as is recommended in clinical guidelines6-7 and NICE TA162, NCCN.